GlucoTrack, Inc. 8-K Filings

Glucotrack, Inc. (GCTK) priced a registered direct offering of 169,388 common shares at $2.04 each and pre-funded warrants to purchase up to 1,350,220 shares at $2.039 each. The warrants are immediately exercisable at $0.001 per share and expire when exercised in full. The company expects approximately $3.1 million in gross proceeds before placement-agent fees and other offering expenses; it expects to use net proceeds to pay off existing debt, with the remainder for working capital and general corporate purposes.

The offering was priced at-the-market under Nasdaq rules and is being conducted on a “best efforts” basis through Dawson James Securities, Inc. The closing is expected on September 25, 2026, subject to customary closing conditions. Glucotrack agreed, subject to exceptions, to restrictions for six months following closing on certain share issuances, registration filings, and Variable Rate Transactions. Its directors and executive officers agreed to 90-day lock-ups after filing of the final prospectus, subject to limited exceptions. Glucotrack agreed to pay Dawson James a cash fee of 8.0% of gross proceeds from sales it arranged.

Glucotrack, Inc. (GCTK) issued a shareholder update on its post-combination structure, LT-100 development and Lōkahi Therapeutics’ ai² platform. Glucotrack Technologies remains a wholly owned subsidiary developing continuous blood glucose monitoring technology, while Lōkahi focuses on therapeutic assets and platform growth. Conversion of the Series A convertible preferred stock remains subject to applicable Nasdaq requirements and other conditions; Glucotrack Technologies is funded under the merger agreement’s resource allocation, while the parent company’s core business and financing allocations are directed to Lōkahi.

LT-100, a biologic program for osteoarthritis knee pain, has a clinical protocol submitted for regulatory review; study initiation is targeted in the near term, subject to regulatory feedback and standard development requirements. The planned study is designed to assess once-weekly subcutaneous injections against the historical regimen of 15 weekly intradermal injections. The ai² Pipeline is supported by a network of more than 14 university partners and industry collaborators and applies due diligence across more than 12,000 decommissioned, deprioritized or abandoned late-stage programs. More than 45 assets met initial screening criteria in its first year, with preliminary business-development discussions underway for certain opportunities. Qare is an early-stage ai² Accelerator initiative.

Glucotrack, Inc. (GCTK) reported that on September 14, 2026, director Paul V. Goode resigned from the Board of Directors, effective immediately. He stated that his resignation was based on his conclusion that there is a potential for a conflict of interest between Glucotrack and its subsidiary in connection with ongoing discussions about implementing the duties, rights and obligations of the entities under the merger agreement relating to the business combination with Lokahi Therapeutics, Inc.

Glucotrack provided Goode with these disclosures in advance and invited him to submit a letter stating whether he agrees with the company’s description; any such letter will be filed as an exhibit to an amended report. His resignation notice is filed as Exhibit 17.1 and incorporated by reference.

Glucotrack, Inc. (GCTK) disclosed that it amended Common Warrants issued in an August 4, 2026 private placement so that neither the holder nor the company may exercise those warrants or issue any related shares until stockholders approve the issuance in accordance with Nasdaq Listing Rule 5635(d).

On September 11, 2026, stockholders at a special meeting approved two stock-issuance proposals tied to existing financings. One covers the full issuance of common shares to White Lion Capital, LLC under a common stock purchase (ELOC) agreement, and the other covers shares issuable upon conversion of senior secured convertible Bridge Notes and exercise of Bridge Warrants, in each case where the issuances may exceed 20% of previously outstanding common stock. A quorum was reached with 3,661,960 shares represented out of 10,578,822 outstanding.

Glucotrack, Inc. (GCTK) entered into a private financing on September 10, 2026, issuing senior secured convertible notes with an aggregate principal of $11,596,172.68, consisting of $4,500,000 in new cash and $4,545,014.69 of existing notes exchanged, reflecting a 22% original issue discount. The notes bear 8% annual interest, increase to 18% upon default, mature nine months from September 10, 2026, and are secured by substantially all company and subsidiary assets on a pari passu basis with existing secured obligations.

The notes are convertible at the lower of $3.12 (the Nasdaq Minimum Price) or 80% of the lowest 15-day VWAP, subject to a floor equal to 20% of the Nasdaq Minimum Price and a 19.99% Exchange Cap unless shareholders approve more. Investors also received 4,831,739 five-year warrants at an exercise price of $7.50 per share, plus registration rights with timing-based share penalties capped at $1,500,000 in value. The company agreed to most-favored-nation protections, restrictions on additional equity issuance and variable-rate financings, and paid Dawson James Securities a 7% cash fee, placement agent warrants, and up to $50,000 in expenses. Gross cash proceeds were $4,500,000 before fees.

Glucotrack, Inc. (GCTK) entered into a Settlement and Release Agreement with Alto Opportunity Master Fund and other parties to resolve disputes related to indebtedness that Alto asserted had an outstanding principal of approximately $10.9 million owed by Apimeds Pharmaceuticals US, Inc. The parties are jointly and severally obligated to pay Alto an initial $2.0 million in cash, another $2.0 million through a convertible promissory note, and up to $125,000 of Alto’s legal fees.

The convertible promissory note bears interest at 5% per annum and is payable in four quarterly installments of $500,000 in principal plus accrued interest, beginning on November 30, 2026 and ending on August 31, 2027. Alto may elect to convert the note’s outstanding principal into Glucotrack common stock at a conversion price of $2.98 per share, subject to customary adjustments, a 9.99% beneficial ownership limitation, and applicable Nasdaq limits on share issuances. The note provides for increased interest and acceleration following events of default, after a five-business-day cure period. The settlement includes customary releases and covenants not to sue, with Alto’s release becoming effective once all required amounts are paid.

Glucotrack, Inc. (GCTK) implemented a 1-for-15 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on August 28, 2026, pursuant to a Certificate of Amendment filed with the Delaware Secretary of State and previously approved by stockholders on August 18, 2026.

Every 15 issued and outstanding shares of common stock were automatically combined into one share, with no change to the par value or to the authorized 250,000,000 common shares. Outstanding shares were reduced from 11,972,157 to approximately 798,144, and related stock options and warrants and their exercise prices were adjusted proportionally. No fractional shares were issued; holdings were rounded up to the next whole share. The common stock will begin trading on a split-adjusted basis on August 31, 2026 under ticker GCTK with new CUSIP 45824Q887.

Glucotrack, Inc. (GCTK) filed an amended current report to add historical and pro forma financial information for Lokahi Therapeutics, Inc. related to a previously completed reverse merger in which Lokahi’s shareholders received 90.0% of the combined company’s fully diluted equity.

Lokahi is a development-stage biopharmaceutical company developing Apitox/LT‑100 for knee osteoarthritis and has no revenue. For the six months ended June 30, 2026, it recorded a net loss of $8.1 million (vs. $3.1 million in 2025) and had cash of $53,186, total assets of $2.5 million, and total liabilities of $9.2 million, resulting in a shareholders’ deficit of $6.7 million. Auditors and management highlight recurring losses, negative operating cash flows and limited cash as raising substantial doubt about Lokahi’s ability to continue as a going concern.

Lokahi’s capital structure includes $5.0 million of secured promissory notes to a trust with $6.1 million due in aggregate and significant near‑term maturities, driving $2.2 million of interest expense in the first half of 2026. Under a settlement with its former parent APUS, Lokahi contributed up to $3.0 million of working capital, assumed related‑party notes, and received a CRO credit facility of about $2.2 million plus full rights to the Apitox program. In the merger with GCTK, Lokahi holders received 1,311,200 GCTK common shares and 785,334 Series A convertible preferred shares, with GCTK’s pre‑merger stockholders retaining a 10.0% minimum fully diluted stake.

Glucotrack, Inc. (GCTK) announced that it will implement a 1-for-15 reverse stock split of its common stock, effective with the opening of trading on August 31, 2026. The stock will continue trading on the Nasdaq Capital Market under the symbol GCTK with a new CUSIP 45824Q887.

Stockholders had previously authorized management on August 18, 2026 to implement one or more reverse splits at ratios up to 1-for-30. The reverse split is intended to help Glucotrack regain compliance with Nasdaq’s $1.00 minimum bid price requirement. After the reverse split, the company must maintain a closing bid of at least $1.00 for each trading day through November 9, 2026 to remain listed, or its securities may be subject to delisting at Nasdaq’s discretion.

Glucotrack, Inc. (GCTK) reported the results of its 2026 annual stockholder meeting. There were 7,719,121 shares of common stock outstanding on the record date, and 2,786,974 votes (about 36.10%) were represented in person or by proxy, constituting a quorum.

Stockholders elected six directors to serve until the 2027 annual meeting. They also approved, on an advisory basis, the 2025 executive compensation, and ratified CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2026.

Stockholders approved amendments to permit one or more reverse stock splits at an aggregate ratio of up to 1-for-30, and approved a warrant inducement involving repricing certain existing warrants, issuing new inducement warrants and issuing common shares upon their exercise, for purposes of complying with Nasdaq Listing Rule 5635(d).

Glucotrack, Inc. amended its July 14, 2026 Common Stock Purchase Agreement with White Lion Capital, LLC. The amendment sets a commitment fee of $1,000,000, to be paid in 2,505,513 shares of common stock issued within one business day after the related resale registration statement becomes effective. A new true-up mechanism requires Glucotrack to pay a cash True-Up Amount if the Commitment Fee Price is below the Minimum Price, equal to $1,000,000 minus 2,505,513 multiplied by the Commitment Fee Price, within 120 days after the Measurement Date. No true-up is owed if the Commitment Fee Price equals or exceeds the Minimum Price. All other terms of the equity line of credit agreement remain in effect, and the commitment share issuance relies on private offering exemptions under Section 4(a)(2) and Rule 506(b) of Regulation D.

Glucotrack, Inc. arranged approximately $5.5 million of new capital with institutional investors, consisting of a $3.5 million follow-on senior secured convertible note financing and a $2.0 million equity-linked private placement. The company stated the $0.75-per-unit equity financing was priced at a premium to market.

The Follow-On Bridge Notes have an aggregate face amount of $4,487,179 (22% original issue discount), bear 8% annual interest, mature nine months from July 14, 2026, carry an 18% default rate, and are secured by a first-priority lien on most company assets. After stockholder approval under Nasdaq Listing Rule 5635(d), they become convertible at the lower of the Nasdaq Minimum Price or 80% of the lowest daily VWAP over 15 trading days, subject to a 20% floor. Follow-On Bridge Warrants become exercisable for five years after approval, with a formula-based exercise price and similar floor protections. In the Interim PIPE, Glucotrack issued 2,666,667 pre-funded warrants and 2,666,667 common warrants (exercise price $1.50) for $2,000,000 in gross proceeds, with a 4.99% (or 9.99%) beneficial ownership cap and resale registration rights under a Registration Rights Agreement.

Glucotrack, Inc., through its wholly owned subsidiary Lōkahi Therapeutics, reported progress on the development strategy for LT-100, aiming to simplify dosing from a historical regimen of up to 15 intradermal injections per treatment visit to a single subcutaneous injection per visit.

In a Type C meeting with the U.S. Food and Drug Administration in May 2026, the company discussed its proposed clinical strategy. A subsequent nonclinical minipig study comparing systemic exposure for subcutaneous versus intradermal administration provided information supporting planned clinical evaluation of the single-injection approach. Subject to ongoing development activities and regulatory review, clinical evaluation of single-injection LT-100 is anticipated as early as the fourth quarter of 2026, with a potential initial readout during the first half of 2027.

Glucotrack, Inc. amended an earlier current report to replace a prior exchange agreement with a new Exchange Agreement dated July 24, 2026, and to file the updated agreement as an exhibit. The new agreement relates to an existing promissory note originally issued on September 12, 2025, with an initial principal of $3,600,000 that has been partially reduced through two prior exchange agreements.

Under the revised terms, the company and an investor partitioned a new $900,000 promissory note (the “Partitioned Note”) from the original note. The investor may exchange all or part of this Partitioned Note into common stock, with the number of shares based on the lower of the last Nasdaq closing price or the five-day average before signing. Exchanges are non-cash and subject to a 9.99% beneficial ownership cap, and the exchange shares are to be delivered on or before August 31, 2026 under exemptions in Sections 4(a)(2) and 3(a)(9) of the Securities Act.

Glucotrack, Inc. entered into an Exchange Agreement on July 22, 2026 with an investor holding a promissory note originally issued on September 12, 2025 in a principal amount of $3,600,000. That note had previously been reduced by $600,000 under an April 13, 2026 exchange agreement and by a further $988,000 under an April 29, 2026 exchange agreement. Under the new agreement, the parties partitioned a new promissory note in the original principal amount of $900,000, referred to as the Partitioned Note, from the existing note.

The outstanding balance of the original note was reduced by the amount of the Partitioned Note, while the original note otherwise remains in effect. The investor may periodically exchange all or part of the Partitioned Note for shares of Glucotrack common stock, with the number of shares determined by dividing the exchanged amount by a “Minimum Price” based on recent Nasdaq Official Closing Prices. Each exchange is a surrender of note principal for shares, with no cash consideration from the investor. Issuances are subject to a 9.99% beneficial ownership limitation, so exchanges may occur in tranches. The Partitioned Note was issued under Section 4(a)(2) of the Securities Act, and the exchange shares rely on the exemption in Section 3(a)(9), with no commissions or other remuneration paid.

Glucotrack, Inc. completed a strategic business combination in which Lōkahi Therapeutics becomes the operating and controlling business of the public company. Lōkahi securityholders received Glucotrack common and Series A preferred stock targeting a 90.0% fully diluted allocation to them, while pre‑merger Glucotrack holders are contractually protected to hold at least 10.0% of fully diluted equity through an Acquiror Stockholder Floor and potential Floor True‑Up Shares. Glucotrack’s legacy continuous blood glucose monitoring business is being transferred into a wholly owned subsidiary that will receive a staged $7,000,000 Subsidiary Contribution and retain all of Glucotrack’s cash and cash equivalents at Closing.

To finance the structure, Glucotrack issued approximately $4.45 million of senior secured convertible promissory notes with a 22% original issue discount, 8% annual interest, nine‑month maturity and Bridge Warrants providing 125% coverage of principal, secured by a first‑priority lien on substantially all assets other than the legacy operating subsidiary, and accompanied by extensive registration, repayment‑from‑proceeds and most‑favored‑nation rights. The company also entered into a three‑year equity line with White Lion Capital for up to $50,000,000 of common stock sales, in exchange for $1,000,000 of commitment shares and a warrant to purchase up to $10,000,000 of stock, plus liquidated damages if key registration and stockholder‑approval deadlines are missed. A new Series A Convertible Preferred Stock (1,000,000 shares, $40.30 Stated Value, 100:1 conversion ratio, no redemption and limited voting rights) will automatically convert into common stock after Acquiror Stockholder Approval and Nasdaq Trading Market Approval. Management changes include appointing Erik Emerson as chief executive officer, while Paul Goode becomes chief technical officer and leads the CBGM subsidiary. The company states that, after these transactions, it believes its stockholders’ equity exceeds Nasdaq’s $2.5 million continued‑listing requirement and is awaiting Nasdaq’s formal determination.

Glucotrack, Inc. has received two Nasdaq deficiency notices that together threaten its continued listing on The Nasdaq Capital Market. The first relates to failure to meet the $1.00 per share minimum bid price requirement under Nasdaq Rule 5550(a)(2). The second, based on its Form 10-Q for the period ended March 31, 2026, states the company no longer meets the $2,500,000 minimum stockholders’ equity requirement under Listing Rule 5550(b)(1) and does not qualify under alternative standards.

The company plans to timely request a hearing before a Nasdaq Hearings Panel by May 18, 2026, which will temporarily stay delisting while it presents a plan to regain compliance. The filing cautions there is no assurance the appeal will succeed or that Glucotrack will be able to regain or maintain compliance with Nasdaq listing rules.

Glucotrack, Inc. reported first quarter 2026 results showing a narrower net loss while advancing its implantable continuous blood glucose monitor program. Net loss was $4.3 million for the quarter, compared with $6.8 million a year earlier, mainly due to a smaller non-cash impact from derivative liabilities.

Research and development expenses were $2.1 million and general and administrative expenses were $2.1 million, both up from the prior year as the company invested in product, manufacturing and corporate infrastructure. Cash and cash equivalents were $3.9 million as of March 31, 2026, down from $7.4 million at December 31, 2025.

The company submitted an Investigational Device Exemption application to the FDA for its fully implantable continuous blood glucose monitoring technology and is targeting a U.S. clinical trial launch in the second half of 2026. Management expects existing cash to fund operations into early third quarter 2026, supporting initiation of the planned U.S. human clinical trial shortly thereafter.

Glucotrack, Inc. has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration to begin a U.S. clinical study of its fully implantable continuous blood glucose monitoring (CBGM) technology.

The system is designed as a long-term, blood-based continuous glucose monitor with no on-body wearable component and a sensor longevity of 3 years, aiming to provide real-time glucose data in a comfortable and discreet form. The IDE submission follows several years of engineering, preclinical evaluation, and iterative design work, and Glucotrack plans to proceed with the U.S. clinical study following FDA review and approval.

Glucotrack, Inc. entered into an Exchange Agreement to swap a $988,000 partitioned promissory note for 1,300,000 shares of its common stock. This is a debt-for-equity exchange with no cash paid by the investor, which reduces note principal while increasing the share count.

The issuance is subject to a 19.9% beneficial ownership limitation, so shares may be issued in tranches and any unexchanged portion of the note will remain outstanding. The company also furnished an updated investor presentation as an exhibit.

Glucotrack, Inc. reported new peer-reviewed data on its fully implantable continuous blood glucose monitoring (CBGM) system from an in-vivo ovine study. Thirty-four devices implanted in 17 adult sheep were followed for up to 240 days and achieved a weighted average Mean Absolute Relative Difference (MARD) of 6.8% across 79 intravenous glucose tolerance tests, indicating high accuracy, with no device-related adverse safety events observed.

The company noted that these preclinical results, together with prior first-in-human data showing a MARD of 7.7% with 99% data capture and no procedure- or device-related serious adverse events, help support its planned IDE submission to the FDA and continued clinical development of its long-life CBGM platform.

Glucotrack, Inc. entered into an Exchange Agreement with an investor to convert a portion of existing debt into equity. The company carved out a new promissory note with an original principal of $600,000, called the Partitioned Note, from a prior $3,600,000 promissory note.

This Partitioned Note will be exchanged for 895,000 shares of common stock, with no cash paid by the investor. Issuance is subject to a 19.9% beneficial ownership limitation, so shares may be delivered in tranches and any remaining balance of the Partitioned Note will stay outstanding until it can be exchanged.

The Partitioned Note was issued under a private placement exemption in Section 4(a)(2), and the exchange shares rely on the Section 3(a)(9) exemption, meaning they are issued solely in exchange for outstanding company securities without additional consideration or commissions.

Glucotrack, Inc. reported its fourth quarter and full year 2025 results and highlighted progress on its implantable continuous blood glucose monitoring (CBGM) technology. The company plans to file an Investigational Device Exemption (IDE) with the FDA in the second quarter of 2026, targeting a U.S. clinical trial launch in the second half of 2026, subject to IDE approval.

In December 2025, Glucotrack raised approximately $4.0 million in gross proceeds through the sale of 1,033,591 shares of common stock (or equivalents) and warrants to purchase up to 2,067,182 shares at a combined effective price of $3.87. For full year 2025, research and development expenses were $9.8 million versus $9.5 million in 2024, and general and administrative expenses were $6.3 million versus $5.1 million.

The 2025 net loss was $19.4 million, improving from a net loss of $22.6 million in 2024, largely due to prior-year non-cash losses. Cash and cash equivalents were $7.4 million at December 31, 2025, up from $5.6 million a year earlier. Management believes existing cash will fund its 2026 operating plan through spring, including the IDE submission and initiation of U.S. human clinical trials.

Glucotrack, Inc. outlined clinical and operational progress that supports its plan to submit an Investigational Device Exemption (IDE) to the FDA for its implantable continuous blood glucose monitoring (CBGM) system in Q2 2026, aiming to start a U.S. clinical trial in the second half of 2026, subject to FDA approval.

The company completed a 5‑day first‑in‑human study in Brazil with 10 participants, achieving a Mean Absolute Relative Difference of 7.7% across 122 matched pairs, 99% data capture, and no procedure or device‑related serious adverse events. A follow‑on feasibility trial in Australia produced similar performance and informed protocol and product refinements.

Glucotrack also secured a U.S. trial site, engaged a CRO experienced in diabetes medtech, and completed targeted design iterations. In 2025 it was awarded three U.S. patents (US 12,453,494; US 12,458,257; US 12,458,258) covering sensor chemistry, intravascular lead design, and low‑power electronics for its three‑year longevity CBGM platform.

Glucotrack, Inc. held a special shareholder meeting where investors approved several key proposals related to future stock issuances and auditor ratification. As of the January 28, 2026 record date, 1,011,279 common shares were outstanding, and 446,348 votes (about 44.1%) were represented, forming a quorum.

Shareholders approved a Nasdaq Stock Issuance (ELOC) Proposal authorizing the full issuance of shares of common stock to Sixth Borough Capital Fund, LP under a September 11, 2025 purchase agreement, which may exceed 20% of shares outstanding on that date. They also approved the Nasdaq Stock Issuance (Warrants) Proposal for the full issuance of shares underlying 2,067,182 common warrants from a December 31, 2025 private placement, with 26,134 votes for and 18,151 against after excluding 100,591 ineligible shares.

In addition, shareholders ratified the appointment of CBIZ CPAs P.C. as independent auditor for the year ended December 31, 2025, with 431,871 votes in favor. An adjournment proposal was not needed because all principal proposals received sufficient support.

Glucotrack, Inc. filed a current report to furnish a press release dated January 29, 2026 under Regulation FD. The company attached the press release as Exhibit 99.1 to provide investors with the same information shared publicly. No financial results or major transactions are described in this excerpt.

Glucotrack, Inc. furnished an update on its business by announcing it issued a press release with financial and operating results for the third quarter ended September 30, 2025.

The press release is attached as Exhibit 99.1 to a Form 8-K dated November 13, 2025, under Item 2.02. The information is furnished, not filed, and therefore is not subject to Section 18 liabilities.

Glucotrack, Inc. permanently adjourned and cancelled its special stockholder meeting after failing to reach a quorum when it reconvened on November 7, 2025. The meeting was originally convened on October 31, 2025 and adjourned due to the absence of a quorum.

As of the September 23, 2025 record date, 158,370 shares of common stock were outstanding and entitled to vote, and 17.6% of those shares were represented in person or by proxy at the reconvened meeting, which did not constitute a quorum under the company’s bylaws. No business was conducted.

Glucotrack, Inc. (GCTK) adjourned its special stockholder meeting after failing to reach a quorum. As of the September 23, 2025 record date, 899,410 shares were outstanding and entitled to vote, and 16.4% were represented in person or by proxy.

Stockholders approved the Adjournment Proposal to solicit additional proxies, with 136,928 votes for, 8,655 against, and 1,923 abstentions. The meeting is adjourned to November 7, 2025 at 12:00 p.m. ET, accessible online at the provided meeting link. At the adjourned session, stockholders will be asked to vote on the Issuance Proposal as described in the company’s definitive proxy statement.

Glucotrack, Inc. furnished a press release under Regulation FD on November 3, 2025. The company submitted the release as Exhibit 99.1 to a current report, using it to provide public information in a way that treats investors fairly. The exhibit is designated as “furnished,” meaning it is not deemed filed for liability purposes under Section 18 of the Exchange Act unless specifically stated otherwise.

Glucotrack, Inc. filed a Form 8-K to report that it issued a press release on October 29, 2025. The company furnished this press release as Exhibit 99.1 under Item 7.01, Regulation FD Disclosure. The filing does not add financial statements or describe specific transaction details.

Glucotrack, Inc. furnished a press release under Item 7.01 (Regulation FD Disclosure) in a Form 8-K. The company attached the press release as Exhibit 99.1.

The company states the information provided under Item 7.01, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act unless specifically indicated otherwise.

GlucoTrack, Inc. entered into a Purchase Agreement and Registration Rights Agreement with Sixth Borough Capital Fund, LP under which the investor committed to purchase up to $20.0 million of the company's common stock, subject to conditions. The facility permits intraday purchases subject to a daily dollar cap of $1,000,000 and a volume limit tied to 100% of five-day average trading volume. Intraday purchases price at the greater of 95% of the lowest intraday trading price or the prior business day closing sale price. The company may pay a Commitment Fee in cash, shares, or pre-funded warrants; if paid in securities those shares will be priced based on a one-day or five-day closing price metric. GlucoTrack must file a registration statement within 15 days covering the commitment fee shares and the maximum purchase shares and use best efforts to have it declared effective within 45 days and to keep it continuously effective for resale until obligations are satisfied.

GlucoTrack (NASDAQ:GCTK) filed an 8-K announcing the issuance of a press release on June 25, 2025. However, the actual content of the press release is not included in this filing. The 8-K serves only as a notice under Regulation FD that a press release was issued and is being furnished as Exhibit 99.1. The filing was signed by Paul Goode, Chief Executive Officer.